Henry Schein/$HSIC
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Henry Schein
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
- Ticker
- $HSIC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 25,000
- Headquarters
- Melville, United States
- Website
- www.henryschein.com
Henry Schein Metrics
BasicAdvanced
$9.5B
23.58
$3.65
0.86
-
Price and volume
Market cap
$9.5B
Beta
0.86
52-week high
$92.18
52-week low
$68.70
Average daily volume
1.5M
Financial strength
Current ratio
1.327
Quick ratio
0.572
Long term debt to equity
0.564
Total debt to equity
0.822
Interest coverage (TTM)
4.80%
Profitability
EBITDA (TTM)
1,097
Gross margin (TTM)
31.59%
Net profit margin (TTM)
3.07%
Operating margin (TTM)
5.78%
Effective tax rate (TTM)
24.14%
Revenue per employee (TTM)
$550,000
Management effectiveness
Return on assets (TTM)
4.39%
Return on equity (TTM)
9.20%
Valuation
Price to earnings (TTM)
23.581
Price to revenue (TTM)
0.716
Price to book
3.01
Price to tangible book (TTM)
-4.68
Price to free cash flow (TTM)
19.663
Free cash flow yield (TTM)
5.09%
Free cash flow per share (TTM)
4.376
Growth
Revenue change (TTM)
6.15%
Earnings per share change (TTM)
15.16%
3-year revenue growth (CAGR)
2.66%
10-year revenue growth (CAGR)
1.97%
3-year earnings per share growth (CAGR)
2.85%
10-year earnings per share growth (CAGR)
1.96%
What the Analysts think about Henry Schein
Analyst ratings (Buy, Hold, Sell) for Henry Schein stock.
Analyst projections of the future price of Henry Schein stock.
Bulls say / Bears say
U.S. dental merchandise sales grew 8.6% in Q3, including 7.0% internal growth, driven mainly by volume and market-share gains. That points to HSIC winning customers in a stable market. (Henry Schein)
Underlying earnings momentum strengthened: Q3 adjusted non-GAAP EPS rose 19.1% after excluding tariff refunds and a prior-year gain, while adjusted EBITDA margin expanded 40 basis points. HSIC raised its 2026 EPS and EBITDA growth outlook, supporting the case that its value-creation work is improving profitability. (Henry Schein)
Global Technology delivered 6.5% internal sales growth and Global Specialty Products 3.4%, offering growth beyond the core distribution business. This gives HSIC multiple routes to expand rather than relying on one segment. (Henry Schein)
The Q3 results and raised full-year EPS outlook include a $0.19-per-share benefit from tariff refunds. That one-off lifts reported earnings but is not a recurring source of growth. (Henry Schein)
Management said some patients are deferring discretionary dental procedures because of out-of-pocket costs, while Brazil remains a market headwind. Those pressures could limit demand in parts of the business. (The Motley Fool)
Q3 internal sales growth was 3.1%, with Global Medical Distribution up only 1.0% and Value-Added Services down 4.8%. Weakness in these areas shows that growth is uneven and leaves the overall top line reliant on stronger dental sales. (Henry Schein)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.
Henry Schein Financial Performance
Revenues and expenses
Henry Schein Earnings Performance
Company profitability
Upcoming events
No upcoming events
Henry Schein News
AllArticlesVideos
Funds containing Henry Schein
AllUSDEURGBP
Fund name | Fund size | $HSIC weighting |
|---|---|---|
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.24% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.24% |
Xtrackers S&P 500 Equal Weight£XDWE | $16B | 0.19% |
Xtrackers S&P 500 Equal Weight$XDEW | $16B | 0.19% |
iShares S&P 500 Equal Weight$EWSX | $5.1B | 0.19% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.